@article{AlmanzarKleinSchmalzingetal.2016,
  author    = {Almanzar, Giovanni and Klein, Matthias and Schmalzing, Marc and Hilligardt, Deborah and El Hajj, Nady and Kneitz, Hermann and Wild, Vanessa and Rosenwald, Andreas and Benoit, Sandrine and Hamm, Henning and Tony, Hans-Peter and Haaf, Thomas and Goebeler, Matthias and Prelog, Martina},
  title     = {Disease Manifestation and Inflammatory Activity as Modulators of Th17/Treg Balance and RORC/FoxP3 Methylation in Systemic Sclerosis},
  series = {International Archives of Allergy and Immunology},
  volume    = {171},
  journal   = {International Archives of Allergy and Immunology},
  number    = {2},
  issn      = {1018-2438},
  doi       = {10.1159/000450949},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-196577},
  pages     = {141-154},
  year      = {2016},
  abstract  = {Background: There is much evidence that T cells are strongly involved in the pathogenesis of localized and systemic forms of scleroderma (SSc). A dysbalance between FoxP3+ regulatory CD4+ T cells (Tregs) and inflammatory T-helper (Th) 17 cells has been suggested. Methods: The study aimed (1) to investigate the phenotypical and functional characteristics of Th17 and Tregs in SSc patients depending on disease manifestation (limited vs. diffuse cutaneous SSc, dcSSc) and activity, and (2) the transcriptional level and methylation status of Th17- and Treg-specific transcription factors. Results: There was a concurrent accumulation of circulating peripheral IL-17-producing CCR6+ Th cells and FoxP3+ Tregs in patients with dcSSc. At the transcriptional level, Th17- and Treg-associated transcription factors were elevated in SSc. A strong association with high circulating Th17 and Tregs was seen with early, active, and severe disease presentation. However, a diminished suppressive function on autologous lymphocytes was found in SSc-derived Tregs. Significant relative hypermethylation was seen at the gene level for RORC1 and RORC2 in SSc, particularly in patients with high inflammatory activity. Conclusions: Besides the high transcriptional activity of T cells, attributed to Treg or Th17 phenotype, in active SSc disease, Tregs may be insufficient to produce high amounts of IL-10 or to control proliferative activity of effector T cells in SSc. Our results suggest a high plasticity of Tregs strongly associated with the Th17 phenotype. Future directions may focus on enhancing Treg functions and stabilization of the Treg phenotype.},
  language  = {en}
}
@article{VaiopoulosKanakisKapsimalietal.2016,
  author    = {Vaiopoulos, Aristeidis G. and Kanakis, Meletios A. and Kapsimali, Violetta and Vaiopoulos, Georgios and Kaklamanis, Phedon G. and Zouboulis, Christos C.},
  title     = {Juvenile Adamantiades-Beh{\c{c}}et disease},
  series = {Dermatology},
  volume    = {232},
  journal   = {Dermatology},
  number    = {2},
  issn      = {1018-8665},
  doi       = {10.1159/000442667},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-196616},
  pages     = {129 -- 136},
  year      = {2016},
  abstract  = {Adamantiades-Beh{\c{c}}et disease (ABD) is a chronic, multisystemic, recurrent, inflammatory vascular disorder of unknown etiology. Patients with symptoms initially appearing at the age of 16 or less are considered as cases of juvenile-onset ABD (JABD). JABD is relatively rare compared to ABD of adults, and only case reports and case studies have been published regarding this subtype of the disease. Epidemiology, clinical features, diagnosis and treatment of JABD are discussed in this review.},
  language  = {en}
}
@article{GiampaoloWojcikSerflingetal.2017,
  author    = {Giampaolo, Sabrina and W{\´o}jcik, Gabriela and Serfling, Edgar and Patra, Amiya K.},
  title     = {Interleukin-2-regulatory T cell axis critically regulates maintenance of hematopoietic stem cells},
  series = {Oncotarget},
  volume    = {8},
  journal   = {Oncotarget},
  number    = {18},
  doi       = {10.18632/oncotarget.16377},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-170947},
  pages     = {29625-29642},
  year      = {2017},
  abstract  = {The role of IL-2 in HSC maintenance is unknown. Here we show that Il2\(^{-/-}\) mice develop severe anomalies in HSC maintenance leading to defective hematopoiesis. Whereas, lack of IL-2 signaling was detrimental for lympho- and erythropoiesis, myelopoiesis was enhanced in Il2\(^{-/-}\) mice. Investigation of the underlying mechanisms of dysregulated hematopoiesis in Il2\(^{-/-}\) mice shows that the IL-2-T\(_{reg}\) cell axis is indispensable for HSC maintenance and normal hematopoiesis. Lack of T\(_{reg}\) activity resulted in increased IFN-γ production by activated T cells and an expansion of the HSCs in the bone marrow (BM). Though, restoring T\(_{reg}\) population successfully rescued HSC maintenance in Il2\(^{-/-}\) mice, preventing IFN-γ activity could do the same even in the absence of T\(_{reg}\) cells. Our study suggests that equilibrium in IL-2 and IFN-γ activity is critical for steady state hematopoiesis, and in clinical conditions of BM failure, IL-2 or anti-IFN-γ treatment might help to restore hematopoiesis.},
  language  = {en}
}
@article{EffenbergerBommertKunzetal.2017,
  author    = {Effenberger, Madlen and Bommert, Kathryn S. and Kunz, Viktoria and Kruk, Jessica and Leich, Ellen and Rudelius, Martina and Bargou, Ralf and Bommert, Kurt},
  title     = {Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation},
  series = {Oncotarget},
  volume    = {8},
  journal   = {Oncotarget},
  number    = {49},
  doi       = {10.18632/oncotarget.20691},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-170168},
  pages     = {85858-85867},
  year      = {2017},
  abstract  = {Multiple Myeloma (MM) is an incurable hematological malignancy affecting millions of people worldwide. As in all tumor cells both glucose and more recently glutamine have been identified as important for MM cellular metabolism, however there is some dispute as to the role of glutamine in MM cell survival. Here we show that the small molecule inhibitor compound 968 effectively inhibits glutaminase and that this inhibition induces apoptosis in both human multiple myeloma cell lines (HMCLs) and primary patient material. The HMCL U266 which does not express MYC was insensitive to both glutamine removal and compound 968, but ectopic expression of MYC imparted sensitivity. Finally, we show that glutamine depletion is reflected by rapid loss of MYC protein which is independent of MYC transcription and post translational modifications. However, MYC loss is dependent on proteasomal activity, and this loss was paralleled by an equally rapid induction of apoptosis. These findings are in contrast to those of glucose depletion which largely affected rates of proliferation in HMCLs, but had no effects on either MYC expression or viability. Therefore, inhibition of glutaminolysis is effective at inducing apoptosis and thus serves as a possible therapeutic target in MM.},
  language  = {en}
}
@phdthesis{Keppler2020,
  author    = {Keppler, Sarah},
  title     = {Characterization of Novel Mutations in Receptor-Tyrosine Kinases in Multiple Myeloma},
  doi       = {10.25972/OPUS-15572},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-155720},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2020},
  abstract  = {Multiple myeloma (MM) is a disease of terminally differentiated B-cells which accumulate in the bone marrow leading to bone lesions, hematopoietic insufficiency and hypercalcemia. Genetically, MM is characterized by a great heterogeneity. A recent next-generation sequencing approach resulted in the identification of a signaling network with an accumulation of mutations in receptor-tyrosine kinases (RTKs), adhesion molecules and downstream effectors. A deep-sequencing amplicon approach of the coding DNA sequence of the six RTKs EPHA2, EGFR, ERBB3, IGF1R, NTRK1 and NTRK2 was conducted in a patient cohort (75 MM samples and 68 corresponding normal samples) of the "Deutsche Studiengruppe Multiples Myelom (DSMM)" to further elucidate the role of RTKs in MM. As an initial approach the detected mutations were correlated with cytogenetic abnormalities and clinical data in the course of this thesis. RTK mutations were present in 13\% of MM patients of the DSMM XI trial and accumulated in the ligand-binding and tyrosine-kinase domain. The newly identified mutations were associated with an adverse patient survival, but not with any cytogenetic abnormality common in MM. Especially rare patient-specific SNPs (single nucleotide polymorphism) had a negative impact on patient survival. For a more comprehensive understanding of the role of rare RTK SNPs in MM, a second amplicon sequencing approach was performed in a patient cohort of the DSMM XII trial that included 75 tumor and 184 normal samples. This approach identified a total of 23 different mutations in the six RTKs EPHA2, EGFR, ERBB3, IGF1R, NTRK1 and NTRK2 affecting 24 patients. These mutations could furthermore be divided into 20 rare SNPs and 3 SNVs (single nucleotide variant). In contrast to the first study, the rare SNPs were significantly associated with the adverse prognostic factor del17p. IGF1R was among the most commonly mutated RTKs in the first amplicon sequencing approach and is known to play an important role in diverse cellular processes such as cell proliferation and survival. To study the role of IGF1R mutations in the hard-to-transfect MM cells, stable IGF1R-knockdown MM cell lines were established. One of the knockdown cell lines (L363-C/C9) as well as a IGF1R-WT MM cell line (AMO1) were subsequently used for the stable overexpression of WT IGF1R and mutant IGF1R (N1129S, D1146N). Overall, an impact on the MAPK and PI3K/AKT signaling pathways was observed upon the IGF1R knockdown as well as upon WT and mutant IGF1R overexpression. The resulting signaling pattern, however, differed between different MM cell lines used in this thesis as well as in a parallel performed master thesis which further demonstrates the great heterogeneity described in MM. Taken together, the conducted sequencing and functional studies illustrate the importance of RTKs and especially of IGF1R and its mutants in the pathogenesis of MM. Moreover, the results support the potential role of IGF1R as a therapeutic target for a subset of MM patients with mutated IGF1R and/or IGF1R overexpression.},
  subject      = {Plasmozytom},
  language  = {en}
}
@phdthesis{Frey2018,
  author    = {Frey, Lea Sarah},
  title     = {Retrospektive Analyse zur Bedeutung des 21-Gen-Tests (OncotypeDX®) f{\"u}r die Indikationsstellung zu einer adjuvanten Chemotherapie bei Hormonrezeptor-positivem, Her2/neu-negativem Mammakarzinom},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-156908},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2018},
  abstract  = {Bei der postoperativen Therapieplanung des Mammakarzinoms treten immer wieder Entscheidungsgrenzf{\"a}lle auf, bei denen keine sicheren Argumente f{\"u}r oder gegen eine adjuvante Chemotherapie gefunden werden k{\"o}nnen. Bei 50 Hormonrezeptor-positiven, Her2/neu-negativen Mammakarzinomen ohne oder mit nur geringer nodaler Metastasierung (max. pT1a) wurde zus{\"a}tzlich zu den konventionellen klinisch-pathologischen Risikofaktoren der OncotypeDX®-Multigentest veranlasst. In der Tumorkonferenz wurde bereits vor Eingang des Testergebnisses ein Votum f{\"u}r oder gegen eine Chemotherapie auf Basis konventioneller Parameter protokolliert; die definitive Therapieempfehlung erfolgte nach Vorliegen des Multigentest-Ergebnisses. 32 Mammakarzinome (64 \%) zeigten einen niedrigen, 26 (32 \%) einen mittleren und 3 (6 \%) einen hohen Recurrence-Score (RS). In vielen F{\"a}llen konnte das OncotypeDX®-Ergebnis eine auf der Basis konventioneller Parameter getroffene Therapieentscheidung st{\"u}tzen. In f{\"u}nf F{\"a}llen wurde eine zun{\"a}chst favorisierte Entscheidung f{\"u}r eine adjuvante Therapie revidiert. In drei F{\"a}llen wurde eine zun{\"a}chst nicht geplante Chemotherapie empfohlen. Allerdings f{\"u}hrte in einigen F{\"a}llen auch eine niedrige oder intermedi{\"a}re Risikokonstellation in der OncotypeDX®-Testung nicht dazu, von einer adjuvanten Chemotherapie abzuraten. Insgesamt spricht das Ergebnis nicht daf{\"u}r, einen Multigentest als Standardmethode einzusetzen. Vielmehr sollten zun{\"a}chst die konventionellen, insbesondere die histopathologischen und immunhistochemischen Parameter mit großer Sorgfalt erhoben und analysiert werden. Im Zweifelsfall und nach Kosten-Nutzen-Abw{\"a}gung kann ein Multigentest jedoch ein weiteres hilfreiches Argument f{\"u}r oder gegen eine bestimmte Therapieempfehlung liefern.},
  subject      = {Mammakarzinom},
  language  = {de}
}
@article{ShiKuaiLeietal.2016,
  author    = {Shi, Yaoyao and Kuai, Yue and Lei, Lizhen and Weng, Yuanyuan and Berberich-Siebelt, Friederike and Zhang, Xinxia and Wang, Jinjie and Zhou, Yuan and Jiang, Xin and Ren, Guoping and Pan, Hongyang and Mao, Zhengrong and Zhou, Ren},
  title     = {The feedback loop of LITAF and BCL6 is involved in regulating apoptosis in B cell non-Hodgkin's-lymphoma},
  series = {Oncotarget},
  volume    = {7},
  journal   = {Oncotarget},
  number    = {47},
  doi       = {10.18632/oncotarget.12680},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-166500},
  pages     = {77444-77456},
  year      = {2016},
  abstract  = {Dysregulation of the apoptotic pathway is widely recognized as a key step in lymphomagenesis. Notably, LITAF was initially identified as a p53-inducible gene, subsequently implicated as a tumor suppressor. Our previous study also showed LITAF to be methylated in 89.5\% B-NHL samples. Conversely, deregulated expression of BCL6 is a pathogenic event in many lymphomas. Interestingly, our study found an oppositional expression of LITAF and BCL6 in B-NHL. In addition, LITAF was recently identified as a novel target gene of BCL6. Therefore, we sought to explore the feedback loop between LITAF and BCL6 in B-NHL. Here, our data for the first time show that LITAF can repress expression of BCL6 by binding to Region A (-87 to +65) containing a putative LITAF-binding motif (CTCCC) within the BCL6 promoter. Furthermore, the regulation of BCL6 targets (PRDM1 or c-Myc) by LITAF may be associated with B-cell differentiation. Results also demonstrate that ectopic expression of LITAF induces cell apoptosis, activated by releasing cytochrome c, cleaving PARP and caspase 3 in B-NHL cells whereas knockdown of LITAF robustly protected cells from apoptosis. Interestingly, BCL6, in turn, could reverse cell apoptosis mediated by LITAF. Collectively, our findings provide a novel apoptotic regulatory pathway in which LITAF, as a transcription factor, inhibits the expression of BCL6, which leads to activation of the intrinsic mitochondrial pathway and tumor apoptosis. Our study is expected to provide a possible biomarker as well as a target for clinical therapies to promote tumor cell apoptosis.},
  language  = {en}
}
@phdthesis{Brenner2016,
  author    = {Brenner, Isabel Katharina},
  title     = {Untersuchungen zu sekretorisch differenzierten Marginalzonen-Lymphomen unter besonderer Ber{\"u}cksichtigung prim{\"a}r kutaner Marginalzonen-Lymphome},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-147237},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2016},
  abstract  = {Marginalzonen-Lymphome (MZL) geh{\"o}ren zur Gruppe der indolenten Non-Hodgkin-Lymphome der B-Zell-Reihe, zu denen nach der aktuellen WHO-Klassifikation auch die prim{\"a}r kutane Marginalzonen-Lymphome (PCMZL) z{\"a}hlen. Eine klonale Leicht- und Schwerkettenexpression kann immunhistochemisch speziell in MZL mit sekretorischer/plasmozytoider Differenzierung (unabh{\"a}ngig von ihrer Prim{\"a}rlokalisation) nachgewiesen werden. In Voruntersuchungen war aufgefallen, dass von prim{\"a}r kutanen MZL ungew{\"o}hnlich h{\"a}ufig IgG bzw. IgG4 exprimiert wird, w{\"a}hrend extrakutane MZL auch nach Literaturangaben eine pr{\"a}ferentielle IgM-Expression aufweisen. In der hier vorgelegten Arbeit wurde die Pr{\"a}valenz einer IgG4-Expression an einer großen Kohorte von sekretorisch/plasmazellul{\"a}r differenzierten MZL untersucht. Hierzu wurde die Immunglobulinschwerkettenexpression an 169 MZL unterschiedlicher Prim{\"a}rlokalisationen immunhistochemisch analysiert. Es konnte gezeigt werden, dass PCMZL {\"u}berzuf{\"a}llig h{\"a}ufig IgG exprimieren (78 \%, 35/49), wobei der Anteil IgG4-positiver PCMZL mit 54 \% (19 von 35) sogar {\"u}ber dem der anderen drei IgG-Subklassen lag (46 \%, 16/35). Unter den 120 anderen, nicht kutanen MZL war lediglich ein okul{\"a}res MZL positiv f{\"u}r die Schwerkette IgG4. Ferner wurde an dem in dieser Arbeit n{\"a}her charakterisierten Kollektiv der PCMZL molekularbiologische Untersuchungen zur Frage einer MyD88 (L265P)-Mutation durchgef{\"u}hrt, die letztendlich in keinem der diesbez{\"u}glich auswertbaren 45 PCMZL nachgewiesen werden konnte.},
  language  = {de}
}
@article{FuchsHartmannErnestusetal.2016,
  author    = {Fuchs, Andreas and Hartmann, Stefan and Ernestus, Karen and Mutzbauer, Grit and Linz, Christian and Brands, Roman C. and K{\"u}bler, Alexander C. and M{\"u}ller-Richter, Urs D. A.},
  title     = {Mandibular intraosseous pseudocarcinomatous hyperplasia: a case report},
  series = {Journal of Medical Case Reports},
  volume    = {16},
  journal   = {Journal of Medical Case Reports},
  number    = {268},
  doi       = {10.1186/s13256-016-1052-y},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-146873},
  year      = {2016},
  abstract  = {Background Mandibular pseudocarcinomatous hyperplasia is a rare and generally benign pathology. We report on one of these rare cases. Case presentation The case history of a 73-year-old white man stated that he had a carcinoma of the oropharynx, which was primarily treated with radiotherapy and chemotherapy 4 years prior. As a result of radiotherapy he developed an osteoradionecrosis of his mandible and a consecutive pathological fracture of his left mandibular angle. Subsequent osteosynthesis was performed with a reconstruction plate. When we first saw him, his reconstruction plate was partially exposed with intraoral and extraoral fistulation. The resected bone of his defect-bordering jaw showed the typical pathohistological findings of an intraosseous mandibular pseudocarcinomatous hyperplasia. After a first reconstruction attempt with an iliac crest graft failed, definitive reconstruction of his mandible with a microvascular anastomosed fibula graft was achieved. Conclusions Intraosseous pseudocarcinomatous hyperplasia of the mandible is a rare differential diagnosis in maxillofacial surgery. Besides other benign epithelial neoplasms, such as calcifying epithelial odontogenic tumor, squamous odontogenic tumor, or different forms of ameloblastoma, the far more frequent invasive squamous cell carcinoma needs to be excluded. A misinterpretation of pseudocarcinomatous hyperplasia as squamous cell carcinoma must be avoided because it can lead to a massive overtreatment.},
  language  = {en}
}
@phdthesis{Zhi2017,
  author    = {Zhi, Yingjun},
  title     = {Immunhistochemische Analyse der Antik{\"o}rper PAT-SM6 und PAT-LM1 auf Kolonkarzinomen und deren Metastasen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-150456},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2017},
  abstract  = {Das kolorektale Karzinom stellt die dritth{\"a}ufigste Tumorerkrankung weltweit dar. Die Risikofaktoren sind vielseitig und werden in exogene und endogene Faktoren eingeteilt. Eine wichtige Pr{\"a}ventionsmaßnahme von Kolonkarzinom ist die komplette endoskopische Koloskopie, die ab dem 55. Lebensjahr empfohlen wird. Der Goldstandard zur Behandlung von Kolonkarzinom ist nach wie vor die chirurgische Tumorresektion mit mikroskopisch nachgewiesener Tumorfreiheit. Eine chirurgische Sanierung der Fernmetastasen, welche am h{\"a}ufigsten in der Leber vorkommen, ist bei betroffenen Patienten anzustreben. Eine adjuvante Chemotherapie wird je nach UICC-Stadium des Tumors durchgef{\"u}hrt. Im Gegensatz zur Behandlung einiger maligner Tumorerkrankungen ist der Einsatz von Antik{\"o}rpern noch kein fester Bestandteil der Therapie von Kolonkarzinomen. In dieser Arbeit wurde Untersuchungsmaterial von 41 Patienten mit Kolonkarzinom, die am Universit{\"a}tsklinikum W{\"u}rzburg in den Jahren 1997 bis 2012 behandelt wurden, analysiert. Dabei wurden Paraffinschnitte vom Prim{\"a}rtumor, regionalen Lymphknotenmetastasen und Lebermetastasen der einzelnen Patienten mit 2 verschiedenen monoklonalen IgM-Antik{\"o}rpern, PAT-SM6 und PAT-LM1, gef{\"a}rbt und mikroskopisch untersucht. Der Antik{\"o}rper PAT-SM6 wurde aus einem an einem Magenkarzinom erkrankten Patienten isoliert und bindet an eine Isotyp-Form des 'Glucose-Regulated' Protein (GRP)-78PAT-SM6. Als Zielstruktur des PAT-LM1 Antik{\"o}rpers wurde eine tumorspezifische Form von NONO (Non-POU domain-containing octamer-binding protein) identifiziert (NONOPAT-LM1). F{\"u}r beide Rezeptor-Isoformen wurde nachgewiesen, dass sie nur auf malignen epithelialen Zellen, nicht aber auf gesunden Zellen exprimiert werden. Anhand dieser Arbeit konnte gezeigt werden, dass PAT-SM6 die Tumorzellen der Lebermetastasen st{\"a}rker anf{\"a}rbte als Zellen des Prim{\"a}rtumors. F{\"u}r die PAT-LM1 Antik{\"o}rperf{\"a}rbung wurde ein {\"a}hnliches Resultat erzielt. In Bezug auf das Lebensalter der Patienten wiesen die Tumorzellen von {\"a}lteren Patienten (ab dem 65. Lebensjahr) eine st{\"a}rkere Antik{\"o}rperbindung durch PAT-SM6 und PAT-LM1 auf. Interessant war auch die Feststellung, dass die Tumorzellen der Lebermetastasen von verstorbenen Patienten durch PAT-LM1 st{\"a}rker gef{\"a}rbt waren als die von zum Untersuchungszeitpunkt noch lebenden Patienten. Die Bindungsunterschiede zwischen PAT-SM6 und PAT-LM1 k{\"o}nnten neue diagnostische und therapeutische M{\"o}glichkeiten bei Kolonkarzinomen bieten und somit zuk{\"u}nftig eine individuelle Tumortherapie erm{\"o}glichen.},
  subject      = {PAT-SM6},
  language  = {de}
}